Using a Blood Test to Monitor Metastatic Breast Cancer Treatment
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety pełnoletnie (powyżej 18 lat) z potwierdzonym rozpoznaniem gruczolakoraka piersi.
- •Choroba nawrotowa lub zaawansowana (przerzuty), która nie nadaje się do leczenia operacyjnego lub radioterapią z zamiarem wyleczenia.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 25, 2025
- Sex
- Female only
Locations (2)
Kingston Health Sciences Centre - Cancer Centre of Southeastern Ontario
Kingston, Canada
Sunnybrook Health Sciences Centre
Toronto, Canada
Trial contact
Christopher R Mueller, Ph.D.
Keira Frosst
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.